<DOC>
	<DOCNO>NCT02017600</DOCNO>
	<brief_summary>Investigator assign 53 patient histologically proven localize squamous cell carcinoma esophagus receive induction chemotherapy regimen ND-420 50 mg/m2 day 1 , cisplatin 70 mg/m2 day1 , plus fluorouracil 700 mg/m2 daily , day1 day4 , every 3 week 2 cycle follow surgical resection . The successful rate complete treatment per protocol complete resection primary variant evaluate study .</brief_summary>
	<brief_title>A Phase II Trial Induction Chemotherapy With ND-420 , Cisplatin Fluorouracil Followed Surgery Treatment Patients With Localized Squamous Cell Carcinoma Esophagus</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients must histologically prove esophageal carcinoma ( squamous cell carcinoma ) . The tumor locally advance ( stage T23/N0 , T13/N+ , technically resectable curative intent ) . Patients must 20 year age . Patients must ECOG performance status score 2 . Patients must life expectancy least 12 week . Patients must accessible treatment followup least one year . Patients must sign informed consent form . Patient must : Hemoglobin level 9 g/dl ; Neutrophil count 1,500/mm3 ; Platelets count 100,000/mm3 ; Serum bilirubin level 1.0 ULN ; Serum transaminase ( GOT , GPT ) level 2.0 ULN ; Serum Alkaline phosphatase level 2.0 ULN ; Serum creatinine level 1.5 mg/dl Creatinine clearance rate ( CrCl ) 60 ml/min institution ( calculate Cockcroft Gault equation ) . Patient receive received concurrent radiotherapy , chemotherapy anticancer treatment esophageal carcinoma . Patients known history severe hypersensitivity reaction medicine drug formulate polysorbate 80 . Major surgery within two week prior enter study , exclude portA insertion feed jejunostomy surgery . Patients CNS metastasis , include clinical suspicion . Patients clinically detectable peripheral neuropathy 2 CTC criterion . Mental statuses patient fit clinical trial . Fertile men woman unless use reliable appropriate contraceptive method . Patients pregnancy lactate , woman consider pregnancy , possible pregnancy without use effective contraception . Patients serious concomitant illness might aggravate chemotherapy , include : Active cardiac disease ( e.g . congestive heart failure , angina , arrhythmia , acute myocardial disease type heart disease require treatment ) within 6 month period precede entry study ; Uncontrolled infection ( e.g . active infection uncontrolled 2 week antibiotic therapy ) ; Retention body fluid ( e.g . pleural effusion , ascites , pericardial effusion , edema need treatment ) ; History esophageal cancer , except curatively treat nonmelanoma skin cancer situ carcinoma esophagus ; condition judge physician 's discretion .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>